PUMA BIOTECHNOLOGY, INC.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | OTHER INFORMATION |
|---|
Trading Plans
During thethree months ended* June 30, 2026*, our directors (as defined in Rule16a-1(f) under the Exchange Act) who adopted or terminated contracts, instructions, written plans or arrangements for the purchase or sale of oursecurities are set forth in the table below:
| Trading Arrangement | Total Shares of Common | |||||
| Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Stock to be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Allison Dorval, Board Member | Adopt | June 16, 2026 | X | Up to 10,193 shares | July 9, 2027 | |
| Alessandra Cesano, Board Member | Adopt | June 15, 2026 | X | Up to 62,150 shares | December 31, 2026 | |
| Troy Wilson, Board Member | Adopt | June 15, 2026 | X | Up to 18,500 shares | June 17, 2027 | |
| Adrian Senderowicz, Board Member | Adopt | June 16, 2026 | X | Up to 27,000 shares | June 25, 2027 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.